FDA approves Zyga to update joint fusion system indications

The US Food & Drug Administration (FDA) has approved the Zyga Technology's request to update indications for use of its SImmetry Sacroiliac Joint Fusion System.

The updated indications for use states the SImmetry Sacroliliac Joint Fusion System is intended for sacroiliac joint fusion for conditions including sacroiliac joint disruptions and degenerative sacroiliitis.

Zyga Technology president and CEO Robert Assell said they believe performing a true, intra-articular arthrodesis of the SI joint provides the best pathway to a successful fusion and a successful patient outcome.